Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating IgPro20 for dermatomyositis in adults was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• IgPro20 (intravenous immunoglobulin 20% solution)

Snippet

Sponsor: CSL Behring | Conditions: Dermatomyositis | Phase 3 | Status: TERMINATED | Results posted: 2025-12-09